ScreenerHero

MBX MBX Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · mbxbio.com
54.54USD-4.18%Mkt Cap: 2.63B $P/E: —

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.63B USD
Enterprise Value2.33B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-86.97M USD
Revenue/Share—
Last Price54.54 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.32
PEG—
EV/EBITDA-19.77
EV/Revenue—
P/S—
P/B6.66
EPS (TTM)-2.30
EPS (Forward)-3.98
52W Range
12.9470% of range72.64
52W High72.64 USD
52W Low12.94 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.56%
ROA-22.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-79.95M USD
CapEx (TTM)1.93M USD
FCF Margin—
FCF Yield-2.02%
Net Debt-415.24M USD
Net Debt/EBITDA3.53
Balance Sheet
Debt/Equity0.00
Current Ratio18.08
Quick Ratio17.82
Book Value/Sh8.54 USD
Cash/Share8.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)94.30 USD
Upside (mean)+72.9%
Target Range70.00 USD – 150.00 USD
70.00+72.9% to mean150.00
# Analysts10
Ownership
Shares Out.48.16M
Float30.99M
Insiders2.82%
Institutions115.94%
Short Interest
Short Ratio10.5d
Short % Float11.98%
Short % Out.8.58%
Shares Short4.13M
Short (prev mo.)4.95M
Technical
SMA 5063.11 (-13.6%)
SMA 20043.65 (+24.9%)
Beta0.10
S&P 52W Chg16.45%
Avg Vol (30d)493.70K
Avg Vol (10d)496.33K
Technical Indicators
RSI (14)38.3
MACD-1.6363
MACD Signal-1.4527
MACD Hist.-0.1836
BB Upper64.39 USD
BB Middle58.88 USD
BB Lower53.38 USD
BB Width18.71%
ATR (14)3.567 USD
Vol Ratio (20d)0.61x